Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or

Nightstar Therapeutics Plc ADR (NITE)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 715,988
  • Shares Outstanding, K 28,100
  • Annual Sales, $ 0 K
  • Annual Income, $ -36,860 K
  • 60-Month Beta 3.24
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 4.77

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 9 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/19
See More
  • Average Estimate -0.35
  • Number of Estimates 2
  • High Estimate -0.34
  • Low Estimate -0.36
  • Prior Year -0.29
  • Growth Rate Est. (year over year) -20.69%

Price Performance

See More
Period Period Low Period High Performance
1-Month
25.39 +0.35%
on 05/08/19
25.72 -0.93%
on 04/25/19
-0.03 (-0.12%)
since 04/18/19
3-Month
14.01 +81.87%
on 02/22/19
25.89 -1.59%
on 03/08/19
+11.30 (+79.69%)
since 02/21/19
52-Week
9.59 +165.69%
on 10/30/18
29.55 -13.76%
on 09/20/18
+11.49 (+82.13%)
since 05/21/18

Most Recent Stories

More News
Nightstar Therapeutics PLC Shareholders Approve Scheme of Arrangement for Acquisition By Biogen at General Meeting and Court Meeting Held on 8 May 2019

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY RESTRICTED JURISDICTION OR ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS...

NITE : 25.48 (+0.16%)
Leading Proxy Advisory Firms ISS and Glass Lewis Recommend Nightstar Shareholders Vote "FOR" Proposed Acquisition by Biogen

WALTHAM, Mass. and LONDON, April 26, 2019 (GLOBE NEWSWIRE) -- Nightstar Therapeutics plc ("Nightstar") (NASDAQ: NITE) today announced that both leading independent proxy advisory firms, Institutional...

NITE : 25.48 (+0.16%)
Market Trends Toward New Normal in WageWorks, Maxwell Technologies, Valeritas, NantKwest, Nightstar Therapeutics PLC Sponsored ADR, and Aspen Group -- Emerging Consolidated Expectations, Analyst Ratings

In new independent research reports released early this morning, Capital Review released its latest key findings for all current investors, traders, and shareholders of WageWorks, Inc. (NYSE:WAGE), Maxwell...

WAGE : 49.31 (-1.69%)
MXWL : 4.45 (-0.67%)
VLRX : 3.77 (-7.82%)
NITE : 25.48 (+0.16%)
ASPU : 4.18 (+0.72%)
NK : 1.07 (+1.90%)
Nightstar (NITE) Merger Investigation: Halper Sadeh LLP Announces Investigation into Whether the Sale of Nightstar Therapeutics Plc is Fair to Nightstar Shareholders - NITE

Halper Sadeh LLP, a global investor rights law firm, announces it is investigating whether the sale of Nightstar Therapeutics plc ("Nightstar" or the "Company") (NASDAQ: NITE) to Biogen Inc. ("Biogen")...

NITE : 25.48 (+0.16%)
Recommended Acquisition of Nightstar Therapeutics plc by Tungsten Bidco Limited, a Wholly-Owned Subsidiary of Biogen Switzerland Holdings GmbH; Posting of Scheme Document

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY RESTRICTED JURISDICTION OR ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS...

NITE : 25.48 (+0.16%)
4 Gene Therapy Players Likely to Become Buyout Targets in 2019

Gene therapy continues to be in focus given the recent spate of deals and acquisitions. We highlight four stocks, which have promising gene therapy candidates in their pipeline.

QURE : 63.49 (+3.95%)
SLDB : 6.09 (+4.82%)
ONCE : 109.05 (+1.29%)
SRPT : 121.19 (+3.08%)
OPHT : 1.39 (-0.71%)
NITE : 25.48 (+0.16%)
RGNX : 43.00 (+2.38%)
BOLD : 39.94 (+2.94%)
Health Day Checkup of Medical ETFs: 5 Top Picks

M&A activity, approval of novel drugs and earnings growth in Q1 put healthcare ETFs in a decent spot.

CELG : 96.25 (+1.50%)
VHT : 167.37 (+1.00%)
XLV : 89.23 (+0.94%)
ONCE : 109.05 (+1.29%)
NITE : 25.48 (+0.16%)
BBH : 120.44 (+1.49%)
BMY : 47.43 (+2.42%)
BTEC : 32.15 (-1.89%)
LLY : 116.58 (+0.30%)
FBT : 132.94 (+2.15%)
IYH : 187.43 (+0.83%)
GSK : 39.39 (unch)
XBI : 83.27 (+3.10%)
Health Day Checkup of Medical ETFs: 5 Top Picks

M&A activity, approval of novel drugs and earnings growth in Q1 put healthcare ETFs in a decent spot.

CELG : 96.25 (+1.50%)
VHT : 167.37 (+1.00%)
XLV : 89.23 (+0.94%)
ONCE : 109.05 (+1.29%)
NITE : 25.48 (+0.16%)
BBH : 120.44 (+1.49%)
BMY : 47.43 (+2.42%)
BTEC : 32.15 (-1.89%)
LLY : 116.58 (+0.30%)
FBT : 132.94 (+2.15%)
IYH : 187.43 (+0.83%)
GSK : 39.39 (unch)
XBI : 83.27 (+3.10%)
INVESTOR ALERT: Monteverde & Associates PC is Investigating the Recently Announced Acquisition

Juan Monteverde, founder and managing partner at Monteverde & Associates PC, a national securities firm headquartered at the Empire State Building in New York City, is investigating:

NITE : 25.48 (+0.16%)
CTL : 10.23 (+0.99%)
BPI : 6.39 (unch)
COTY : 13.51 (+0.07%)
HF : 44.26 (+0.36%)
GTXI : 1.03 (-0.96%)
Biotech Stock Roundup: BIIB to Acquire Nightstar, Other Pipeline News & More

Key highlights of the past week are merger agreements plus regulatory and pipeline developments.

CELG : 96.25 (+1.50%)
NITE : 25.48 (+0.16%)
IMGN : 1.95 (+0.52%)
REGN : 309.95 (+2.44%)
BIIB : 232.92 (+0.94%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 16% Buy with a Weakening short term outlook on maintaining the current direction.

Longer term, the trend strength is Weak. Long term indicators fully support a continuation of the trend.

See More Share

Trade NITE with:

Business Summary

Nightstar Therapeutics Limited is a clinical-stage gene therapy company. It focused on developing and commercializing novel one-time treatments for patients suffering from rare inherited retinal diseases including choroideremia, X-linked retinitis pigmentosa and Best vitelliform macular dystrophy. The...

See More

Key Turning Points

2nd Resistance Point 25.53
1st Resistance Point 25.50
Last Price 25.48
1st Support Level 25.45
2nd Support Level 25.43

See More

52-Week High 29.55
Last Price 25.48
Fibonacci 61.8% 21.92
Fibonacci 50% 19.57
Fibonacci 38.2% 17.21
52-Week Low 9.59

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar